FDA Approval Alert: The Need-to-Know | Liso-Cel for Relapsed/Refractory CLL/SLL

The FDA has approved lisocabtagene maraleucel as a treatment for adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.